
Opinion|Videos|August 7, 2024
AYA ALL: Role of Asparaginase Erwinia Chrysanthemi
Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.
Advertisement
Video content above is prompted by the following questions:
- Please comment on the trial led to the approval of use for asparaginase erwinia chrysanthemi in AYA ALL.
- How does for asparaginase erwinia chrysanthemi work?
- What are your thoughts on the key efficacy outcomes?
Advertisement
Related to this article

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
3
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
4
Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC
5

